- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about MSSTF
Recent news which mentions MSSTF
Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes
October 07, 2024
From Benzinga
Hope For Postpartum Depression: This Company To Launch Clinical Trial On Next-Gen Psychedelic
September 18, 2023
Tickers
MSSTF
From Benzinga
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
September 05, 2023
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Reunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3
June 29, 2023
From Benzinga
UK Greenlights Phase 2 Clinical Trial On Mindset Pharma's Psilocin Drug For Major Depression
June 27, 2023
Tickers
MSSTF
From Benzinga
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
May 01, 2023
From Benzinga
This Firm Bets On Non-Hallucinogenic Psychedelics, Files Claims For International IP Protection
April 26, 2023
Tickers
MSSTF
From Benzinga
From Benzinga
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
March 20, 2023
From Benzinga
Two Major Psychedelics Companies Take Novel Chemical Entity Patent Battle To Federal Court
March 14, 2023
From Benzinga
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
March 13, 2023
From Benzinga
Australia Receives First Batch Of Clinical-Grade Psilocybin From Mindset Pharma And PharmAla
March 06, 2023
From Benzinga
Silo Pharma, Mindset Pharma, Terran Biosciences Receive Psychedelic Treatments Patents, IP Portfolios Expanded
February 03, 2023
From Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
January 25, 2023
From Benzinga
From Benzinga
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
November 21, 2022
From Benzinga
These Two Psychedelics Companies Team Up In An Exclusive Sales Deal, Here Are The Details
November 16, 2022
Tickers
MSSTF
From Benzinga
EXCLUSIVE: Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo, Market Subverticals & Informal Guidance
November 07, 2022
From Benzinga
European Psychedelics Research Group Nabs $2M In Seed Funding As Clinical Research Picks Up Speed
October 11, 2022
From Benzinga
Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
October 07, 2022
From Benzinga
From Benzinga
Mindset Pharma Meets With UK Regulator: Is A Phase 1 Trial Getting Close?
September 14, 2022
Tickers
MSSTF
From Benzinga
Psychedelics Companies Explore & Protect Their Findings, This Firm Is Doing That In 16 Countries
September 07, 2022
Tickers
MSSTF
From Benzinga
Psychedelic Stock Gainers And Losers From September 7, 2022
September 07, 2022
From Benzinga
Most, But Not All, Psychedelics Companies Have Sufficient Liquidity
September 06, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.